1. Home
  2. AEVA vs IMCR Comparison

AEVA vs IMCR Comparison

Compare AEVA & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

AEVA

Aeva Technologies Inc.

HOLD

Current Price

$23.51

Market Cap

1.3B

ML Signal

HOLD

IMCR

Immunocore Holdings plc

HOLD

Current Price

$28.62

Market Cap

1.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AEVA
IMCR
Founded
2019
2008
Country
United States
United Kingdom
Employees
239
N/A
Industry
Auto Parts:O.E.M.
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.4B
IPO Year
N/A
2016

Fundamental Metrics

Financial Performance
Metric
AEVA
IMCR
Price
$23.51
$28.62
Analyst Decision
Strong Buy
Buy
Analyst Count
4
10
Target Price
$26.50
$66.33
AVG Volume (30 Days)
2.6M
395.8K
Earning Date
05-06-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
30.39
EPS
N/A
0.25
Revenue
N/A
$249,428,000.00
Revenue This Year
$85.37
$14.57
Revenue Next Year
$132.72
$8.21
P/E Ratio
N/A
$111.60
Revenue Growth
N/A
43.05
52 Week Low
$8.83
$27.56
52 Week High
$38.79
$40.71

Technical Indicators

Market Signals
Indicator
AEVA
IMCR
Relative Strength Index (RSI) 54.97 46.34
Support Level $12.37 $28.09
Resistance Level $29.82 $31.11
Average True Range (ATR) 2.95 1.31
MACD -0.63 -0.04
Stochastic Oscillator 33.98 31.30

Price Performance

Historical Comparison
AEVA
IMCR

About AEVA Aeva Technologies Inc.

Aeva Technologies Inc through its Frequency Modulated Continuous Wave (FMCW) sensing technology, designs a 4D LiDAR-on-chip that, along with its proprietary software applications, has the potential to enable the adoption of LiDAR across broad applications from automated driving to consumer electronics, consumer health, industrial automation, and security application. The 4D LiDAR sensors are designed to detect both velocity and position, supporting perception and decision-making in automated systems. The company operates in North America, EMEA, and Asia. The company's revenue consists of sales of perception solutions or sensing systems and non-recurring engineering services. Geographically, it derives the majority of its revenue from North America.

About IMCR Immunocore Holdings plc

Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.

Share on Social Networks: